Financings Of The Fortnight: IPOs Dominate Early 2014 With 13 Debuts In As Many Days
This article was originally published in The Pink Sheet Daily
Executive Summary
Insider participation continues to play an important role in getting a majority of biotech IPOs off the ground; and it’s not clear if or when that trend will change. Plus, news on recent financings by Dicerna, uniQure, Lumos Pharma and NightstaRx.